GOT1 and metabolic dysfunction-associated steatotic liver disease: Similarly, intake of products containing ACNs had no significant effect on AST concentrations in patients with NAFLD patients (Chang et al., 2014; Zhang et al., 2015), pre‐diabetes (Yang, Ling, Yang, et al., 2017), diabetes (Mohtashami et al., 2019; Soltani et al., 2015; Yang, Ling, Yang, et al., 2017), and hyperlipidemia (Kianbakht et al., 2014; Soltani et al., 2014).